GenomeScan is partnering with Olink Proteomics to bring proteomics to the next level by enabling high-throughput analysis of thousands of proteins, while using less than a drop of blood.
Olink’s PEA technology that is based on dual antibody recognition results in the coupling of DNA oligonucleotides and boasts exceptional levels of specificity, sensitivity and dynamic range.
By combining different omics approaches, GenomeScan helps facilitates researchers in identifying the regulators of biological processes, identifying new targets for drug discovery, evaluating therapeutic interventions, and identifying biomarkers that can be used for diagnosis, prognosis, and disease monitoring, leading to more precise and effective treatments.
Researchers at Leiden University Medical Center (LUMC) have mapped the mechanism of action of a promising new antibiotic. Under a cryo-electron microscope, researchers Mia Urem...
Leiden, November 12 - The project “Omics in the Polder” from Leiden University of Applied Sciences has been nominated for the RAAK Award. This award is presented annually to the...
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...